Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Edwards Lifesciences Corp., ROE, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The analysis of the annual financial data reveals several key trends in the company's profitability and financial position over the examined period.

Net Income
Net income exhibited general growth with fluctuations throughout the years. Starting at $79.3 million in 2005, net income increased modestly until 2009, reaching a peak of $229.1 million. After remaining relatively stable around the $200 million to $300 million range from 2010 to 2013, a significant surge occurred by 2014, with net income rising sharply to $811.1 million. A decline followed in 2015 and 2016, with net income dropping to approximately $495 million and $570 million, respectively. Subsequent years showed gradual increases, culminating in a notable peak at $1.503 billion in 2021, representing the highest value in the period.
Stockholders’ Equity
Stockholders’ equity demonstrated consistent and steady growth over the period. Starting at $690 million in 2005, equity increased each year with no declines. The growth accelerated notably from 2010 onward, rising from $1.3 billion to nearly $2.2 billion by 2014 and continuing up to $5.8 billion by 2021. This trend indicates strengthening capital base and retained earnings expansion, supporting the company’s financial stability and ability to fund operations and growth.
Return on Equity (ROE)
ROE trends show variability corresponding with net income performance. Starting at 11.49% in 2005, ROE increased unevenly to a high of 37.01% in 2014, reflecting strong profitability relative to equity at that time. Post-2014, ROE showed fluctuations between roughly 18% and 26%, reaching the period peak of 25.76% in 2021. The pattern suggests periods of improved profit efficiency interspersed with some moderation, likely influenced by changes in net income growth and equity changes.

Overall, the data depicts a company experiencing substantial growth in equity and profitability over the evaluated years, albeit with some volatility in annual net income and ROE. The strong upward trends in net income and equity, accompanied by relatively high and improving ROE levels especially in recent years, indicate solid financial health and effective utilization of capital.


Comparison to Competitors

Edwards Lifesciences Corp., ROE, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Health Care Equipment & Services)

Edwards Lifesciences Corp., ROE, long-term trends, comparison to sector (health care equipment & services)

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)

Edwards Lifesciences Corp., ROE, long-term trends, comparison to industry (health care)

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).